Daratumumab enhances treatment efficacy in newly diagnosed multiple myeloma, showing improved MRD negativity and ...

Yelak Biru was diagnosed with multiple myeloma at 25 and given just a few years to live. Thirty years later, he's thriving.

A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; Carvykti) ...

Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI ® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ...

Johnson & Johnson shared positive ASCO 2025 results, including improved survival and remission in prostate and multiple ...

A phase 3 trial did not support a transplant-based approach for patients who already achieved MRD negativity or a tandem ...

The cell therapy proved superior to standard-of-care regardless of cytogenetic risk or prior therapy in the CARTITUDE-4 study ...

J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at ...

Multiple myeloma (MM) is an incurable haematological malignancy, but patient survival outcomes have been lately improved by ...

The FDA is expected to decide on treatments for multiple myeloma, NSCLC, melanoma, phenylketonuria, and 2 rare kidney diseases.

New research, from COMy 2025, has found that specific senescence-associated biomarkers are significantly correlated with ...

In the two decades since a young father was diagnosed with multiple myeloma, clinical trials and advances in treating his ...